Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary

E. Chuang, N. Wiener, P. Christos, R. Kessler, M. Cobham, D. Donovan, G. L. Goldberg, T. Caputo, A. Doyle, L. Vahdat, Joseph A. Sparano

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer. Methods: Patients with recurrent ovarian or breast carcinoma received PLD every 3 or 4 weeks plus five different dose schemas of ixabepilone in cohorts of three to six patients. Results: Thirty patients received a total of 142 treatment cycles of the PLD-ixabepilone combination. The recommended phase II dose and schedule of ixabepilone was 16 mg/m2 on days 1, 8, and 15 plus PLD 30 mg/m2 given on day 1, repeated every 4 weeks. Hand-foot syndrome and mucositis were dose limiting when both ixabepilone and PLD were given every 3 or 4 weeks. Objective responses were observed in 3 of 13 patients (23%) with breast cancer and 5 of 17 patients (29%) with ovarian cancer. Conclusion: Ixabepilone may be safely combined with PLD, but tolerability is highly dependent upon the scheduling of both agents. This combination demonstrated efficacy in patients with breast and ovarian cancer and merits further evaluation in these settings.

Original languageEnglish (US)
Pages (from-to)2075-2080
Number of pages6
JournalAnnals of Oncology
Volume21
Issue number10
DOIs
StatePublished - Mar 31 2010

Fingerprint

Ovary
Adenocarcinoma
Breast
Ovarian Neoplasms
Breast Neoplasms
Hand-Foot Syndrome
Mucositis
liposomal doxorubicin
ixabepilone
Appointments and Schedules
Cell Line

Keywords

  • Breast cancer
  • Ixabepilone
  • Liposomal doxorubicin
  • Ovarian cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. / Chuang, E.; Wiener, N.; Christos, P.; Kessler, R.; Cobham, M.; Donovan, D.; Goldberg, G. L.; Caputo, T.; Doyle, A.; Vahdat, L.; Sparano, Joseph A.

In: Annals of Oncology, Vol. 21, No. 10, 31.03.2010, p. 2075-2080.

Research output: Contribution to journalArticle

Chuang, E, Wiener, N, Christos, P, Kessler, R, Cobham, M, Donovan, D, Goldberg, GL, Caputo, T, Doyle, A, Vahdat, L & Sparano, JA 2010, 'Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary', Annals of Oncology, vol. 21, no. 10, pp. 2075-2080. https://doi.org/10.1093/annonc/mdq080
Chuang, E. ; Wiener, N. ; Christos, P. ; Kessler, R. ; Cobham, M. ; Donovan, D. ; Goldberg, G. L. ; Caputo, T. ; Doyle, A. ; Vahdat, L. ; Sparano, Joseph A. / Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary. In: Annals of Oncology. 2010 ; Vol. 21, No. 10. pp. 2075-2080.
@article{da8d784e498944acabd2b46f7b9fc92f,
title = "Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary",
abstract = "Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer. Methods: Patients with recurrent ovarian or breast carcinoma received PLD every 3 or 4 weeks plus five different dose schemas of ixabepilone in cohorts of three to six patients. Results: Thirty patients received a total of 142 treatment cycles of the PLD-ixabepilone combination. The recommended phase II dose and schedule of ixabepilone was 16 mg/m2 on days 1, 8, and 15 plus PLD 30 mg/m2 given on day 1, repeated every 4 weeks. Hand-foot syndrome and mucositis were dose limiting when both ixabepilone and PLD were given every 3 or 4 weeks. Objective responses were observed in 3 of 13 patients (23{\%}) with breast cancer and 5 of 17 patients (29{\%}) with ovarian cancer. Conclusion: Ixabepilone may be safely combined with PLD, but tolerability is highly dependent upon the scheduling of both agents. This combination demonstrated efficacy in patients with breast and ovarian cancer and merits further evaluation in these settings.",
keywords = "Breast cancer, Ixabepilone, Liposomal doxorubicin, Ovarian cancer",
author = "E. Chuang and N. Wiener and P. Christos and R. Kessler and M. Cobham and D. Donovan and Goldberg, {G. L.} and T. Caputo and A. Doyle and L. Vahdat and Sparano, {Joseph A.}",
year = "2010",
month = "3",
day = "31",
doi = "10.1093/annonc/mdq080",
language = "English (US)",
volume = "21",
pages = "2075--2080",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Phase I trial of ixabepilone plus pegylated liposomal doxorubicin in patients with adenocarcinoma of breast or ovary

AU - Chuang, E.

AU - Wiener, N.

AU - Christos, P.

AU - Kessler, R.

AU - Cobham, M.

AU - Donovan, D.

AU - Goldberg, G. L.

AU - Caputo, T.

AU - Doyle, A.

AU - Vahdat, L.

AU - Sparano, Joseph A.

PY - 2010/3/31

Y1 - 2010/3/31

N2 - Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer. Methods: Patients with recurrent ovarian or breast carcinoma received PLD every 3 or 4 weeks plus five different dose schemas of ixabepilone in cohorts of three to six patients. Results: Thirty patients received a total of 142 treatment cycles of the PLD-ixabepilone combination. The recommended phase II dose and schedule of ixabepilone was 16 mg/m2 on days 1, 8, and 15 plus PLD 30 mg/m2 given on day 1, repeated every 4 weeks. Hand-foot syndrome and mucositis were dose limiting when both ixabepilone and PLD were given every 3 or 4 weeks. Objective responses were observed in 3 of 13 patients (23%) with breast cancer and 5 of 17 patients (29%) with ovarian cancer. Conclusion: Ixabepilone may be safely combined with PLD, but tolerability is highly dependent upon the scheduling of both agents. This combination demonstrated efficacy in patients with breast and ovarian cancer and merits further evaluation in these settings.

AB - Background: Ixabepilone is a semisynthetic epothilone B analogue that is active in taxane-resistant cell lines and has shown activity in patients with refractory breast and ovarian cancer. We carried out a phase I trial of ixabepilone plus pegylated liposomal doxorubicin (PLD) in patients with advanced taxane-pretreated ovarian and breast cancer. Methods: Patients with recurrent ovarian or breast carcinoma received PLD every 3 or 4 weeks plus five different dose schemas of ixabepilone in cohorts of three to six patients. Results: Thirty patients received a total of 142 treatment cycles of the PLD-ixabepilone combination. The recommended phase II dose and schedule of ixabepilone was 16 mg/m2 on days 1, 8, and 15 plus PLD 30 mg/m2 given on day 1, repeated every 4 weeks. Hand-foot syndrome and mucositis were dose limiting when both ixabepilone and PLD were given every 3 or 4 weeks. Objective responses were observed in 3 of 13 patients (23%) with breast cancer and 5 of 17 patients (29%) with ovarian cancer. Conclusion: Ixabepilone may be safely combined with PLD, but tolerability is highly dependent upon the scheduling of both agents. This combination demonstrated efficacy in patients with breast and ovarian cancer and merits further evaluation in these settings.

KW - Breast cancer

KW - Ixabepilone

KW - Liposomal doxorubicin

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=77957148050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957148050&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq080

DO - 10.1093/annonc/mdq080

M3 - Article

C2 - 20357034

AN - SCOPUS:77957148050

VL - 21

SP - 2075

EP - 2080

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 10

ER -